{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:42:40Z","timestamp":1777916560893,"version":"3.51.4"},"reference-count":0,"publisher":"Esmon Publicidad, SA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Sanid Penit"],"abstract":"<jats:p>Objectives: Direct-acting antivirals (DAAs) share pharmacokinetic pathways with many comedications commonly administered to patients living with chronic hepatitis C virus (HCV) infection (PLWHCV). International guidelines recommend a thorough drug-drug interaction (DDI) risk assessment prior to starting DAA therapy and before starting comedications. This study aims to evaluate the impact of potential multiple DDIs in the real-life adverse event (AE) profile of PLWHCV treated with DAAs. Material and method: This is a retrospective, observational study using electronic medical records. Patients included were PLWHCV and were treated with either the protease inhibitor (PI) free DAA sofosbuvir\/velpatasvir (SOF\/VEL) or glecaprevir\/pibrentasvir (GLE\/PIB) between 2017 and 2020. Potential (single and multiple) DDIs were identified using the Liverpool HEP Interaction Checker. AEs potentially associated to DDIs were identified during DAA treatment period. Results: 1620 patients with DAA prescriptions (SOF\/VEL or GLE\/PIB) were included. Of these, 123 were predicted to have multiple DDIs (multi-DDI). About 10% (123\/1256) of the patients receiving \u22652 comedications were at risk of multi-DDI with DAA. Most comedication-associated AEs were recorded in this multi-DDI population (88.9%, 16\/18), meaning that 13% (16\/123) of the multi-DDI population suffered AEs. According to DAA regimen, more comedication-associated AEs were reported in GLE\/PIB-treated as compared with SOF\/VEL-treated patients (18.3% [13\/71] vs 5.8% [3\/52] p&lt;0.05). These AEs were mainly reported by primary care physicians (62.5%). Discussion: PLWHCV predicted to have multiple DDIs are at high risk of AEs. Moreover, fewer comedication-associated AEs were identified with the PI-free DAA SOF\/VEL as compared with GLE\/PIB.<\/jats:p>","DOI":"10.18176\/resp.00095","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:55:42Z","timestamp":1730886942000},"page":"98-112","source":"Crossref","is-referenced-by-count":7,"title":["Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain"],"prefix":"10.18176","volume":"26","author":[{"given":"Juan","family":"Turnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Garc\u00eda-Herola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Morillo-Verdugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinela","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1ndido","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Sicras-Mainar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7491","published-online":{"date-parts":[[2024,11,5]]},"container-title":["Revista Espa\u00f1ola de Sanidad Penitenciaria"],"original-title":["English"],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:55:50Z","timestamp":1730886950000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.sanipe.es\/OJS\/index.php\/RESP\/article\/view\/681\/1348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,5]]}},"URL":"https:\/\/doi.org\/10.18176\/resp.00095","relation":{},"ISSN":["2013-6463"],"issn-type":[{"value":"2013-6463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}